Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer

[1]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[2]  H. Kanayama,et al.  Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. , 1998, Cancer.

[3]  D Pinkel,et al.  Mechanisms of inactivation of E-cadherin in breast cancer cell lines. , 1998, Cancer research.

[4]  M. Nakajima,et al.  Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. , 1998, British Journal of Cancer.

[5]  David Sidransky,et al.  Detection of bladder cancer recurrence by microsatellite analysis of urine , 1997, Nature Medicine.

[6]  B. Blumenstein,et al.  Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. , 1997, Urology.

[7]  O. Yoshida,et al.  Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. , 1997, Journal of the National Cancer Institute.

[8]  A. Akdaş,et al.  Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. , 1997, British journal of urology.

[9]  S. Kagawa,et al.  Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. , 1997, British journal of urology.

[10]  Kazuhiro Yoshida,et al.  Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine , 1997, Cancer.

[11]  D. Neal,et al.  Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. , 1996, British Journal of Cancer.

[12]  E. Messing,et al.  Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. , 1996, The Journal of urology.

[13]  Y S Erozan,et al.  Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis , 1996, Science.

[14]  L. Baert,et al.  Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. , 1996, The Journal of urology.

[15]  K. Syrigos,et al.  E‐cadherin expression in bladder cancer using formalin‐fixed, paraffin‐embedded tissues: Correlation with histopathological grade, tumour stage and survival , 1995, International journal of cancer.

[16]  C. Sheehan,et al.  E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. , 1995, Human pathology.

[17]  S. Hirohashi,et al.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Schellhammer,et al.  Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. , 1995, The Journal of urology.

[19]  H. Höfler,et al.  Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. , 1995, Journal of the National Cancer Institute.

[20]  M. Parmar,et al.  The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. , 1995, British journal of urology.

[21]  W. H. Porter,et al.  Soluble forms of the adhesion molecule E-cadherin in urine. , 1995, Journal of clinical pathology.

[22]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[23]  S. Nagata,et al.  Soluble fragments of e-cadherin cell-adhesion molecule increase in urinary-excretion of cancer-patients, potentially indicating its shedding from epithelial tumor-cells. , 1994, International journal of oncology.

[24]  S. Hirohashi,et al.  Point Mutation of the E–Cadherin Gene in Invasive Lobular Carcinoma of the Breast , 1994, Japanese journal of cancer research : Gann.

[25]  W. Birchmeier,et al.  Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. , 1994, Cancer research.

[26]  K. Nakagawa,et al.  Soluble E-cadherin fragments increased in circulation of cancer patients. , 1994, British Journal of Cancer.

[27]  T. Sheldon,et al.  Quantification of proteinuria: a re-evaluation of the protein/creatinine ratio for elderly subjects. , 1993, Age and ageing.

[28]  A. Gearing,et al.  Circulating adhesion molecules in disease. , 1993, Immunology today.

[29]  M. Takeichi.  Cadherins in cancer: implications for invasion and metastasis. , 1993, Current opinion in cell biology.

[30]  J. Schalken,et al.  Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. , 1993, Cancer research.

[31]  M. Takeichi,et al.  Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid. , 1992, British Journal of Cancer.

[32]  S. Hirohashi,et al.  Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. , 1992, Cancer research.

[33]  J. Engel,et al.  Single amino acid substitutions in one Ca2+ binding site of uvomorulin abolish the adhesive function , 1990, Cell.

[34]  L S Freedman,et al.  Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). , 1989, The Journal of urology.

[35]  D. Solter,et al.  Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue , 1983, Cell.

[36]  L. Hemmingsen,et al.  Urinary protein profiles in patients with urothelial bladder tumours. , 1981, British journal of urology.

[37]  A. Monaco,et al.  Urinary proteins as biological markers: bladder cancer diagnosis versus urinary tract infection. , 1980, The Journal of urology.

[38]  A. Monaco,et al.  Qualitative analysis of proteinuria associated with bladder cancer. , 1979, Investigative urology.

[39]  L. Jones,et al.  Glomerular antigen complexes associated with transitional cell carcinoma. , 1975, Surgery, gynecology & obstetrics.

[40]  E. Will,et al.  Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  M. Takeichi,et al.  Cadherins: a molecular family important in selective cell-cell adhesion. , 1990, Annual review of biochemistry.

[42]  B. Johansson.  Urinary protein patterns in patients with uroepithelial tumours. Effect of surgery and radiotherapy. , 1975, Scandinavian journal of urology and nephrology.

[43]  B. Johansson,et al.  Proteinuria in patients with uroepithelial tumours with special regard to tumour size, clinical staging and grade of malignancy. , 1975, Scandinavian journal of urology and nephrology.